GUIDEMRD

GUIding multi-moDal thErapies against MRD by liquid biopsies

Public consultation on the Ideal Healthcare Pathway for Integrating ctDNA Testing for MRD Detection in Clinical Practice

Help Shape the Future of Cancer Care!

We invite you to participate in this public consultation on integrating circulating tumor DNA (ctDNA) testing for Minimal Residual Disease (MRD) detection into cancer care pathways.

Your insights will help develop an ideal healthcare pathway that addresses the needs of diverse healthcare systems and cancer types.

Whether you're a healthcare provider, patient, caregiver, or industry professional, your voice is essential in co-creating a more effective healthcare pathway for better patient outcomes.

This document will equip you with the information needed to participate in the public consultation.

Consultation Objectives

- Gather insights on how ctDNA testing for MRD detection can be incorporated across various European healthcare systems, considering diverse cancer types and regional differences.
- Foster an ongoing dialogue with key stakeholders, helping to shape, refine, and validate the draft Ideal Healthcare Pathway.

Consultation Timeline

October 28th, 2024 - November 18th, 2024

Whose voice is important?

- Healthcare providers & practitioners with expertise in oncology care
- Healthcare researchers & academics
- People living with cancer & survivors of cancer (cancer types: non-metastatic lung, pancreatic & colorectal cancer)
- Family members and caregivers
- Patient advocacy groups & representatives
- Pharmaceutical and biotech professionals
- Anyone else with an interest in enhancing cancer care

What's next?

1. **First, please read the information below** to understand the project & purpose of this public consultation.
2. **Please click here** to learn more about the current & draft ideal healthcare pathway.
3. **Please share your input through this survey**. This should take less than 15 minutes. If you have any questions, please contact Eleonora at: eleonora@thesynergist.org

Scan the QR Code or copy the link in the search bar

bit.ly/GuideMRD-public-consultation

About the Project

GUIDE.MRD

GUIDE.MRD (GUIding multi-moDal thErapies against MRD by liquid biopsies) is a European project funded by the Innovative Health Initiative of the European Commission. It is a public-private partnership of leading academics, industry, patient organizations, and other experts aiming to improve the standard of cancer care for lung, pancreatic, and colorectal cancers. The 5-year project focuses on exploring blood tests, referred to as "liquid biopsies," that can help guide treatment choices for cancer patients after surgery and improve patient outcomes.

It aims to define standards for ctDNA tests in the context of MRD detection and use these standards to evaluate current tests. When ready, the standards will be made public so they can be used widely. The project will rank existing liquid biopsy tests based on their accuracy in identifying patients as ctDNA positive or negative. The best ctDNA blood tests will be used in a clinical study to compare their accuracy against actual treatment outcomes. The most accurate ctDNA tests will then have a good potential to help doctors and patients choose the best treatment options. More information can be found here.

Co-creating an Ideal Healthcare Pathway Map

As part of our work to understand stakeholder needs and expectations in healthcare pathways, we are collaborating with patients, caregivers, patient advocates, and healthcare professionals (HCPs) to co-create an "ideal" healthcare pathway. This pathway will incorporate the use of ctDNA testing and multi-modal therapies to support shared clinical decision-making and improve patient outcomes.

The goal is to develop a common understanding of both clinical and patient pathways, highlighting the role of ctDNA standards in enhancing shared decisions between patients and HCPs. We will explore potential barriers and challenges in these pathways, offering solutions from both patient and healthcare provider perspectives.

The final outcome will be a collaboratively designed map showing the clinical and patient journeys, focusing on key actions, needs, and attention points, especially in the post-operative and pre-recurrence phases of care related to GUIDE.MRD.

Click here to learn more about the ideal healthcare pathway drafted in collaboration with patients & HCPs.

Consultation Overview

The consultation will cover the following key areas:

- Awareness and Educational Gaps in ctDNA for Minimal Residual Disease (MRD) Testing.
- Optimal Timing for ctDNA Testing in the Care Pathway.
- Impact of ctDNA testing for MRD detection on Patient Outcomes and Treatment Decisions.
- Evaluating Access Challenges and Barriers to MRD Detection through ctDNA Testing.
- Identifying Ethical Concerns and Emotional Impacts of ctDNA Testing for MRD Detection.
- Cross-border Collaboration for Improved Access to MRD Detection through ctDNA Testing.
- Additional Insights for an Ideal Healthcare Pathway.

Take 15 minutes to complete the survey and make a real impact on the future of cancer care!

Click **here** to subscribe to our newsletter

Click the icon below and follow us on LinkedIn:

Start the Survey Now!

bit.ly/GuideMRD-public-consultation